PL2904009T3 - Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w - Google Patents
Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-wInfo
- Publication number
- PL2904009T3 PL2904009T3 PL13770926T PL13770926T PL2904009T3 PL 2904009 T3 PL2904009 T3 PL 2904009T3 PL 13770926 T PL13770926 T PL 13770926T PL 13770926 T PL13770926 T PL 13770926T PL 2904009 T3 PL2904009 T3 PL 2904009T3
- Authority
- PL
- Poland
- Prior art keywords
- openonia
- mielinization
- herv
- blocking
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Oncology (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708779P | 2012-10-02 | 2012-10-02 | |
| US201261746792P | 2012-12-28 | 2012-12-28 | |
| PCT/EP2013/070452 WO2014053489A1 (en) | 2012-10-02 | 2013-10-01 | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
| EP13770926.7A EP2904009B1 (en) | 2012-10-02 | 2013-10-01 | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2904009T3 true PL2904009T3 (pl) | 2019-06-28 |
Family
ID=49274655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13770926T PL2904009T3 (pl) | 2012-10-02 | 2013-10-01 | Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w |
| PL18198309T PL3447070T3 (pl) | 2012-10-02 | 2013-10-01 | Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18198309T PL3447070T3 (pl) | 2012-10-02 | 2013-10-01 | Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9840550B2 (pl) |
| EP (2) | EP3447070B9 (pl) |
| JP (2) | JP6379331B2 (pl) |
| KR (1) | KR102098033B1 (pl) |
| CN (2) | CN105709224B (pl) |
| AU (2) | AU2013326552B2 (pl) |
| BR (1) | BR112015007150A8 (pl) |
| CA (1) | CA2882781C (pl) |
| CY (2) | CY1121237T1 (pl) |
| DK (2) | DK3447070T3 (pl) |
| EA (2) | EA037253B1 (pl) |
| EC (1) | ECSP15014925A (pl) |
| ES (2) | ES2710748T3 (pl) |
| HR (2) | HRP20190274T1 (pl) |
| HU (2) | HUE043419T2 (pl) |
| IL (3) | IL237474A0 (pl) |
| IN (1) | IN2015DN02397A (pl) |
| LT (2) | LT2904009T (pl) |
| MX (2) | MX366846B (pl) |
| MY (1) | MY172209A (pl) |
| PL (2) | PL2904009T3 (pl) |
| PT (2) | PT2904009T (pl) |
| RS (2) | RS58320B1 (pl) |
| RU (1) | RU2636355C2 (pl) |
| SA (1) | SA515360207B1 (pl) |
| SG (1) | SG11201501274VA (pl) |
| SI (2) | SI3447070T1 (pl) |
| SM (1) | SMT201900087T1 (pl) |
| UA (1) | UA119032C2 (pl) |
| WO (1) | WO2014053489A1 (pl) |
| ZA (1) | ZA201501491B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2949342A1 (en) * | 2014-05-28 | 2015-12-02 | Geneuro SA | Antiretroviral drug targeting human endogenous retrovirus |
| EP3351265A1 (en) * | 2017-01-20 | 2018-07-25 | Geneuro SA | Anti-herv-k envelope antibody and uses thereof |
| JP7122002B2 (ja) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| US20210405011A1 (en) * | 2018-09-01 | 2021-12-30 | National University Corporation Hokkaido University | Pharmaceutical for preventing and/or treating stress load-related disease |
| US20220332799A1 (en) * | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| EP1265989A2 (en) * | 2000-03-21 | 2002-12-18 | MS Research A/S | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| CA2433877C (en) * | 2001-01-17 | 2014-11-18 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
| US20090233888A1 (en) * | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| EP2139467B1 (en) * | 2007-02-08 | 2016-09-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
| WO2009062926A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
| SMT201700366T1 (it) * | 2008-07-08 | 2017-09-07 | Geneuro Sa | Uso terapeutico di ligando specifico in malattie associate a msrv |
| WO2010045265A1 (en) * | 2008-10-13 | 2010-04-22 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| WO2010148323A2 (en) * | 2009-06-18 | 2010-12-23 | Whittemore Peterson Institute For Neuro-Immune Disease | Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus |
| HUE025878T2 (en) * | 2010-02-12 | 2016-05-30 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
-
2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko not_active Expired - Fee Related
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja active Active
- 2013-10-01 HR HRP20190274TT patent/HRP20190274T1/hr unknown
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh not_active Expired - Fee Related
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 MX MX2019008916A patent/MX385003B/es unknown
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en not_active Ceased
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en not_active Ceased
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
- 2013-10-01 US US14/429,199 patent/US9840550B2/en not_active Expired - Fee Related
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh not_active Expired - Fee Related
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 SM SM20190087T patent/SMT201900087T1/it unknown
-
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
-
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja not_active Expired - Fee Related
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
-
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en not_active Ceased
-
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
-
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
-
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| IL235512B (en) | Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| PT3060237T (pt) | Proteína de reprogramação modificada para utilização no tratamento de um cancro | |
| PL3010910T3 (pl) | Związki pirymidynodionu przeciwko chorobom serca | |
| BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
| HUE043171T2 (hu) | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek | |
| PL2717692T3 (pl) | Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych | |
| PL2768493T3 (pl) | Fitokannabinoidy do stosowania w leczeniu raka piersi | |
| IL244089A0 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| HUE051632T2 (hu) | Betegségek kezelésére szolgáló készítmények és eljárások | |
| IL229858B (en) | Polypeptides and uses thereof for tratment of autoimmune disorders and infection | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| IL234606B (en) | Novel methods and composition for treatment of disease | |
| LT2914254T (lt) | Kombinacinės terapijos chemoresistencinių vėžių gydymui | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| LT2958624T (lt) | Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas | |
| BR112014026553A2 (pt) | Fralda descartável | |
| IL264382B (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein | |
| HUE047920T2 (hu) | GD2-pozitív rák kezelésére szolgáló készítmények |